PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: BioNet-Asia Co., Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BioNet-Asia to License Recombinant Pertussis Strain - BioNet-Asia Co., Ltd, announced the signature with a China-based company of a binding letter of intent to license a Bordetella pertussis strain, genetically modified to express antigens - BioNet-Asia.com
BioNet-Asia to License Recombinant Pertussis Strain

 

NewswireToday - /newswire/ - Bangkok, Thailand, 2012/01/13 - BioNet-Asia Co., Ltd, announced the signature with a China-based company of a binding letter of intent to license a Bordetella pertussis strain, genetically modified to express antigens - BioNet-Asia.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BioNet-Asia Co., Ltd, a vaccine-focused biotech company based in Thailand has announced today the signature with a China-based company of a binding letter of intent to license a Bordetella pertussis strain, genetically modified to express antigens that can be used in the development of acellular pertussis-based vaccines.

Acellular Pertussis Vaccines are now routinely and successfully used to prevent whooping cough disease, in Western Europe, North America, Japan and Korea but not in the emerging countries because of the high cost.

The advantages of the recombinant pertussis strain producing very high yields of inactivated pertussis toxins enable the production of a recombinant Acellular Pertussis Vaccine to be affordable in China and other developing countries.

Mr Vitoon Vonghangool, Managing Director of BioNet-Asia said “This is an important milestone because it is the outcome of years of research and development in Thailand.
Our company has been heavily affected by the floods in October 2011 and it was important to find a partner interested in our recombinant pertussis strain. We expect to receive double-digit million dollars over a period of 10 years followed by royalties. Upfront payments are expected within this year and will be used to reconstruct our facilities.”
Dr Pham Hong Thai, Managing Director of BioNet-Asia concluded that “The agreement will be signed within a couple of months and we are also in discussion with some vaccine manufacturers for collaboration on recombinant acellular pertussis based vaccines.”

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: BioNet-Asia Co., Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BioNet-Asia to License Recombinant Pertussis Strain

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: BioNet-Asia.com 
+662 361 8110 info[.]bionet-asia.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any BioNet-Asia Co., Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From BioNet-Asia Co., Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)